NASDAQ: ARQTArcutis Biotherapeutics Inc Stock
$14.91+0.16 (+1.08%)
Updated Apr 30, 2025
ARQT Price
$14.91
Fair Value Price
N/A
Market Cap
$1.77B
52 Week Low
$6.99
52 Week High
$17.75
P/E
-12.85x
P/B
11.23x
P/S
8.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$196.54M
Earnings
-$140.04M
Gross Margin
90.3%
Operating Margin
-57.1%
Profit Margin
-71.3%
Debt to Equity
1.22
Operating Cash Flow
-$112M
Beta
1.19
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ARQT Overview
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARQT's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ARQT
Ranked#18 of 462
Ranked#18 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ARQT news, forecast changes, insider trades & much more!
ARQT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARQT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARQT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ARQT is poor value based on its book value relative to its share price (11.23x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
ARQT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ARQT due diligence checks available for Premium users.
Valuation
ARQT fair value
Fair Value of ARQT stock based on Discounted Cash Flow (DCF)
Price
$14.91
Fair Value
-$8.18
Undervalued by
282.19%
ARQT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ARQT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.85x
Industry
-162.28x
Market
29.18x
ARQT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.23x
Industry
4.45x
ARQT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARQT's financial health
Profit margin
Revenue
$71.4M
Net Income
-$10.8M
Profit Margin
-15.1%
ARQT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ARQT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$348.9M
Liabilities
$191.3M
Debt to equity
1.22
ARQT's short-term assets ($335.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARQT's short-term assets ($335.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARQT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARQT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$748.0k
Investing
$34.9M
Financing
-$97.4M
ARQT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARQT vs Biotech Stocks
Arcutis Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.